Sandoz launches biosimilar Filgrastim BS Injection 75 µg/150 µg/ 300 µg Syringe in Japan
Tokyo, Japan, December 1, 2014 ― Sandoz, the generic pharmaceutical division of Novartis, today announced the launch in Japan of biosimilar Filgrastim BS Injection 75µg / 150µg / 300µg Syringe. Filgrastim is used with certain cancer patients to acceler…